CGTX — Cognition Therapeutics Share Price
0.000.00%
Last trade - 00:00- $23.08m
- -$1.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.23 | ||
| Price to Tang. Book | 1.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -282.66% | ||
| Return on Equity | -157.19% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
Directors
- Lisa Ricciardi PRE (60)
- Susan Catalano CFD
- James O'Brien CFO
- Stephen Sands DRC
- Peggy Wallace DRC
- Ellen Richstone IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 21st, 2007
- Public Since
- October 8th, 2021
- No. of Shareholders
- 280
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 61,972,946
- Address
- Suite 261, 2403 Sidney Street, PITTSBURGH, 15203
- Web
- https://cogrx.com/
- Phone
- +1 4127701621
- Auditors
- Ernst & Young LLP
Upcoming Events for CGTX
Similar to CGTX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Cognition Therapeutics share price?
As of Today at 20:00 UTC, shares in Cognition Therapeutics are trading at $0.37. This share price information is delayed by 15 minutes.
How has the Cognition Therapeutics share price performed this year?
Shares in Cognition Therapeutics last closed at $0.37 and the price had moved by -80.4% over the past 365 days. In terms of relative price strength the Cognition Therapeutics share price has underperformed the S&P500 Index by -81.57% over the past year.
What are the analyst and broker recommendations for Cognition Therapeutics?
The overall consensus recommendation for Cognition Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cognition Therapeutics dividend yield?
Cognition Therapeutics does not currently pay a dividend.
Does Cognition Therapeutics pay a dividend?
Cognition Therapeutics does not currently pay a dividend.
When does Cognition Therapeutics next pay dividends?
Cognition Therapeutics does not currently pay a dividend.
How do I buy Cognition Therapeutics shares?
To buy shares in Cognition Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cognition Therapeutics?
As of the previous close price of $0.37, shares in Cognition Therapeutics had a market capitalisation of $23.08m.
Where are Cognition Therapeutics shares listed?
Here are the trading details for Cognition Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CGTX
What kind of share is Cognition Therapeutics?
Based on an overall assessment of its quality, value and momentum Cognition Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cognition Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Cognition Therapeutics is $5.40. That is 1350.05% above the last closing price of $0.37.
Analysts covering Cognition Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.41 for the next financial year.
Find out moreWhat is the trend in the Cognition Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cognition Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -16.53%.
As of the last closing price of $0.37, shares in Cognition Therapeutics were trading -45.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cognition Therapeutics PE Ratio?
The Cognition Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cognition Therapeutics?
Cognition Therapeutics' management team is headed by:
- Lisa Ricciardi - PRE
- Susan Catalano - CFD
- James O'Brien - CFO
- Stephen Sands - DRC
- Peggy Wallace - DRC
- Ellen Richstone - IND